Product information and disease descriptionProduct descriptionProduct information
Special populations
18 evidence topics · 9 sources
Older adults: exposure in elderly compared with young healthy participants
Chinese adults: bridging study and ethnic differences
Renal impairment: effect on kidney function
Renal impairment: renal function eligibility criteria
Renal impairment: dedicated pharmacokinetic study
No evidence found.
Hepatic impairment: compensated liver disease eligibility criteria
Hepatic impairment: cirrhosis and abnormal synthetic liver function as exclusion criteria
Hepatic impairment: dedicated pharmacokinetic study
No evidence found.
Autoimmune liver or thyroid disease: exclusion added after a suspected unexpected serious adverse reaction
Type 2 diabetes: histologic and glycemic response in participants with diabetes
Prediabetes: participants without type 2 diabetes
“Among 144 patients without T2D, 47 (33%) had prediabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart failure: exclusion criteria
Anemia: hemoglobin exclusion threshold
Pregnancy: placental distribution and reproductive toxicity in animals
Pregnancy, breastfeeding, and contraception: trial requirements
Ovulation resumption: listed among important risks of the therapeutic class
Pediatric population: age criterion of 18 years or older
Pediatric population: pediatric studies
No evidence found.